U.S. Job Growth Slows, Puts Economy’s Soft Landing In View

WSJ What’s News

The Wall Street Journal

Daily News, News

4.1 • 4.2K Ratings

🗓️ 8 December 2023

⏱️ 13 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

P.M. Edition for Dec. 8. The U.S. labor market’s gradual cooling extended into November, the Labor Department reported. WSJ reporter Amara Omeokwe discusses the renewed optimism that the economy is on track for a soft landing. And the U.S. has approved the world’s first medicine to employ Crispr technology—a gene-modifying tool—for patients suffering from sickle-cell disease. Biotechnology reporter Joseph Walker has more. Pierre Bienaimé hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	This episode is brought to you by Delive a Rule, because anything goes this Christmas.
0:06.0	Yes, even sprouts on a pizza or gravy on sushi.
0:10.0	The rules are, there are no rules. Have a Cantonese on Christmas Eve or a
0:15.2	Balty on Boxing Day and when you're so over the leftovers bring on the ramen
0:20.2	From big brands to local favorites this Christmas it's all on your doorstep with
0:25.0	deliver room. Geographical restrictions, Ties and C service and delivery fees apply. The US approved the world's first medical treatment using gene editing CRISPR technology,
0:40.0	and US job growth slows down in November.
0:42.8	This report is renewing optimism that the economy can achieve a potential soft landing,
0:49.5	which is where we see inflation come down without triggering a recession.
0:54.4	Plus, antitrust regulators in the UK are taking a closer look at the partnership between
0:58.9	Microsoft and Open AI.
1:00.9	It's Friday, December 8th.
1:02.4	I'm Pierre B'nay for the Wall Street Journal sitting
1:04.4	in for Emory Fertoli. This is the PM edition of What's News, the top headlines and business
1:08.6	stories that moved the world's first medicine to use CRISPR technology.
1:19.0	A gene-modifying tool discovered just over a decade ago.
1:22.0	The new treatment,
1:23.4	Kasevie, was developed by Vertex Pharmaceuticals and CRISPR therapeutics,
1:27.5	and it was cleared for people with severe forms of sickle cell disease,
1:31.3	a painful genetic condition that mainly affects black people.
1:35.0	Joseph Walker covers biotechnology for the Wall Street Journal, and he joins me now.
1:38.8	Joseph, how does this treatment work?
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Wall Street Journal, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Wall Street Journal and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.